Unknown PHASE2 INTERVENTIONAL 1-arm NCT04412564

A Study of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

A Open-label, Single-arm Phase Ⅱ Clinical Trial of TQ-B3101 Capsules in Subjects With Advanced Malignant Tumor

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Interventions TQ-B3101

Updated 8 times since 2020 Last updated: Aug 16, 2020 Started: Aug 5, 2020 Primary completion: Mar 31, 2021 Completion: Sep 30, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT04412564, this PHASE2 trial focuses on Advanced Malignant Tumor and remains ongoing. Sponsored by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., it has been updated 8 times since 2020, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

8 versions recorded

Dec 2025 — Present [monthly]

Unknown PHASE2
Sep 2025 — Dec 2025 [monthly]

Unknown PHASE2
Sep 2024 — Sep 2025 [monthly]

Unknown PHASE2
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE2

Status: Unknown Status → Unknown
Nov 2022 — Jul 2024 [monthly]

Unknown Status PHASE2

Status: Recruiting → Unknown Status

▶ Show 3 earlier versions

Jan 2021 — Nov 2022 [monthly]

Recruiting PHASE2
Sep 2020 — Jan 2021 [monthly]

Recruiting PHASE2

Status: Not Yet Recruiting → Recruiting
Jul 2020 — Sep 2020 [monthly]

Not Yet Recruiting PHASE2

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Data source: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Anyang, China , Beijing, China , Changsha, China , Dalian, China , Fuzhou, China , Guangzhou, China , Hangzhou, China , Harbin, China , Hefei, China , Kashgar Prefecture, China and 14 more locations